There is emerging evidence that PROs are a useful tool in oncology to enhance patient-physician communication as well as improving symptom control and treatment response monitoring. They are broadly defined as “any report of the status of a patient’s health condition that comes directly from the patient, without interpretation of the patient’s response by a clinician or anyone else”. Functional and HRQoL outcomes can be evaluated with patient reported outcomes (PROs) which capture the patients’ subjective effects of illness and treatment. Limited lifespan of patients with HGG and impact of both tumour and treatment shift the scope of care beyond survival towards optimising functional outcomes and improving HRQoL. These have a negative impact on health-related quality of life (HRQoL) which represents the patient’s general perception of the effect of the illness and treatment on physical, psychological, and social aspects of life. The diagnosis of HGG and impact of multimodal treatment options can be associated with functional decline, cognitive impairment, and a deteriorating psycho-social well-being. Current standard treatment for GBM includes maximal safe surgical resection, radiotherapy (RT) and chemotherapy with temozolomide. They are highly heterogenous tumours, arising from glial cells in the central nervous system of which WHO Grade IV glioblastoma multiforme (GBM) is the most predominant and aggressive with a median survival time of 15 months with treatment. World Health Organisation (WHO) Grade III and IV classified high-grade gliomas (HGG) account for 60–75% of all adult gliomas.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |